Advertisement
Canada markets closed

  • S&P/TSX

    21,969.24
    +83.86 (+0.38%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CAD/USD

    0.7316
    -0.0007 (-0.09%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • Bitcoin CAD

    85,741.00
    -2,495.14 (-2.83%)
     

  • CMC Crypto 200

    1,306.95
    -89.59 (-6.41%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • RUSSELL 2000

    2,002.00
    +20.88 (+1.05%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ

    15,927.90
    +316.14 (+2.03%)
     

  • VOLATILITY

    15.03
    -0.34 (-2.21%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     

Wall Street Fundamentals Releases New In-Depth Stock Reports on ARWR, EPZM, NVAX and XOMA

ACCESSWIRE

Shares of major biotech companies continued to stumble Monday on concerns the sector may be overheated. The iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB - News) and the SPDR S&P Biotech ETF (NYSEARCA:XBI - News) posted declines of 2.76 percent and 4.02 percent Monday. "We still see more downside risk than upside reward for the sector given how extremely extended it has become on a longer-term timeframe," said MKM Partners' chief market technician, Jonathan Krinsky, in a note to clients. Here is how some biotech companies reacted Monday:

Arrowhead Research Corp. (NASDAQ:ARWR - News) shares traded in the range of $15.97 to $21.09 Monday before settling to close at $17.37, a decrease of 16.09 percent. The stock appears to be facing some resistance at the $19.32 and $20.70 levels with some support at $14.52 and $13.00. Shares of Arrowhead Research are up approximately 60.0 percent year-to-date.

More information on Arrowhead Research and access to the free equity report can be found at:
www.WallStreetFundamentals.com/ARWR

Epizyme Inc. (NASDAQ:EPZM - News) shares traded in the range of $23.00 to $26.68 Monday before settling to close at $23.80, a decrease of 10.79 percent. The stock appears to be facing some resistance at the $26.04 and $27.29 levels with some support at $23.69 and $21.96. Shares of Epizyme are up approximately 15.0 percent year-to-date.

ADVERTISEMENT

More information on Epizyme and access to the free equity report can be found at:
www.WallStreetFundamentals.com/EPZM

Novavax, Inc. (NASDAQ:NVAX - News) shares traded in the range of $3.94 to $4.72 Monday before settling to close at $4.13, a decrease of 11.75 percent. The stock appears to be facing some resistance at the $4.79 and $5.01 levels with some support at $3.87 and $3.35. Shares of Novavax are down approximately 20.0 percent year-to-date.

More information on Novavax and access to the free equity report can be found at:
www.WallStreetFundamentals.com/NVAX

XOMA Corp. (NASDAQ:XOMA - News) shares traded in the range of $5.40 to $6.05 Monday before settling to close at $5.41, a decrease of 10.73 percent. The stock appears to be facing some resistance at the $76.55 and $78.35 levels with some support at $73.45 and $71.97. Shares of XOMA are down approximately 12.0 percent year-to-date.

More information on XOMA and access to the free equity report can be found at:
www.WallStreetFundamentals.com/XOMA

Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.

Activate your always free membership by signing up at www.WallStreetFundamentals.com today.

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:

Wall Street Fundamentals
Website: www.WallStreetFundamentals.com
Email: editor@wallstreetfundamentals.com